异基因造血干细胞移植后植入功能不良研究进展

[1]	Sun YQ,He GL,Chang YJ,et al.The incidence,risk factors,and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation[J].Ann Hematol,2015,94:1699-1705.
[2]	Chang YJ,Zhao XY,Xu LP,et al.Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation:a prospective study with randomly assigned training and validation sets[J].J Hematol Oncol,2015,8:84.
[3]	Lee KH,Lee JH,Choi SJ,et al.Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation-frequency and outcomes[J].Bone Marrow Transplant,2004,33:729-734.
[4]	Larocca A,Piaggio G,Podestà M,et al.Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation[J].Haematologica,2006,91:935-940.
[5]	师辰燕,Mamal A,刘增慧,等.重型再生障碍性贫血行异基因造血干细胞移植后植入功能不良的危险因素分析[J].中华血液学杂志,2017,38(9):761-766.
[6]	Xiao Y,Song J,Jiang Z,et al.Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation[J].Int J Med Sci,2014,11:652-657.
[7]	Alchalby H,Yunus DR,Zabelina T,et al.Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis[J].Bone Marrow Transplant,2016,51:1223-1227.
[8]	Reisner Y,Martelli MF.Transplantation tolerance induced by "mega dose" CD34+cell transplants[J].Exp Hematol,2000,28:119-127.
[9]	Zhao Y,Gao F,Shi J,et al.The incidence,Risk factors,and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant,2019 Jun 6.pii:S1083-8791(19)30361-1.doi:10.1016/j.bbmt.2019.05.036.[Epub ahead of print].
[10]	Peralvo J,Bacigalupo A,Pittaluga PA,et al.Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation[J].Bone Marrow Transplant,1987,2:279-285.
[11]	Ciurea SO,Cao K,Fernadez-Vina M,et al.The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation[J].Bone Marrow Transplant,2018,53:521-534.
[12]	Yoshihara S,Maruya E,Taniguchi K,et al.Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT[J].Bone Marrow Transplant,2012,47:508-515.
[13]	Shen H,Yu H,Liang PH,et al.An acute negative bystander effect of gamma-irradiated recipients on transplanted hematopoietic stem cells[J].Blood,2012,119:3629-3637.
[14]	Zhao HY,Lyu ZS,Duan CW,et al.An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation[J].Br J Haematol,2018,182:679-692.
[15]	Wang YT,Kong Y,Song Y,et al.Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Funct ion after Allogeneic Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant,2016,22:1376-1382.
[16]	Kong Y,Wang YT,Cao XN,et al.Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation[J].J Transl Med,2017,15:57.
[17]	Zeng L,Chen C,Song G,et al.Infusion of endothelial progenitor cells accelerates hematopoietic and immune reconstitution,and ameliorates the graft-versus-host disease after hematopoietic stem cell transplantation[J].Cell Biochem Biophys,2012,64:213-222.
[18]	Kong Y,Chang YJ,Wang YZ,et al.Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant,2013,19:1465-1473.
[19]	Song Y,Zhao HY,Lyu ZS,et al.Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant,2018,24:1981-1989.
[20]	Moirangthem RD,Singh S,Adsul A,et al.Hypoxic niche-mediated regeneration of hematopoiesis in the engraftment window is dominantly affected by oxygen tension in the milieu[J].Stem Cells Dev,2015,24:2423-2436.
[21]	Chatterjee R,Law S.Epigenetic and microenvironmental alterations in bone marrow associated with ROS in experimental aplastic anemia[J].Eur J Cell Biol,2018,97:32-43.
[22]	Kong Y,Song Y,Hu Y,et al.Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants[J].Oncotarget,2016,7:30892-30906.
[23]	Stasia A,Ghiso A,Galaverna F,et al.CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation[J].Biol Blood Marrow Transplant,2014,20:1435-1454.
[24]	Haen SP,Schumm M,Faul C,et al.Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation[J].J Cancer Res Clin Oncol,2015,141:2241-2251.
[25]	费新红,贺俊宝,程昊钰,等.纯化供者CD34⁺细胞输注治疗单倍型造血干细胞移植后移植物功能不良12例临床分析[J].中华血液学杂志,2018,39(10):828-832.
[26]	Klyuchnikov E,El-Cheikh J,Sputtek A,et al.CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies[J].Biol Blood Marrow Transplant,2014,20:382-386.
[27]	Mainardi C,Ebinger M,Enkel S,et al.CD34+selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation[J].Br J Haematol,2018,180:90-99.
[28]	Ghobadi A,Fiala MA,Ramsingh G,et al.Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation[J].Biol Blood Marrow Transplant,2017,23:1072-1077.
[29]	Mtiller I,Kordowich S,Holzwarth C,et al.Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation[J].Blood Cells Mol Dis,2008,40:125-132.
[30]	Kim DW,Chung YJ,Kim TG,et al.Cotransplantation of third party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation[J].Blood,2004,103:1941-1948.
[31]	Liu X,Wu M,Peng Y,et al.Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors:a pilot prospective study[J].Cell Transplant,2014,23:1087-1098.
[32]	Shi MM,KongY,Song Y,et al.Atorvastatin enhances endothelial cell function in posttransplant poor graft function[J].Blood,2016,128:2988-2999.
[33]	Liesveld JL.Trouble in the niche?Send in a statin[J].Blood,2016,128:2877-2878.
[34]	Kong Y,Shi MM,Zhang YY,et al.N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation[J].Am J Hematol,2018,93:931-942.
[35]	Kong Y,Wang Y,Zhang YY,et al.Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation[J].Blood Adv,2019,3:1303-1317.
[36]	Master S,Dwary A,Mansour R,et al.Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation[J].Case Rep Oncol,2018,11:191-195.
[37]	Tang C,Chen F,Kong D,et al.Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag[J].J Hematol Oncol,2018,11:103.
[38]	Marotta S,MaranoL,Ricci P,et al.Eltrombopag for post-transplant cytopenias due to poor graft function[J].Bone Marrow Transplant,2019 Jan 24.doi:10.1038/s41409-019-0442-3.[Epub ahead of print].